- ByInvesting.com-
Investing.com -- Goldman Sachs has shifted its ratings stance on European chemicals, moving to a more pro-cyclical view and...
Last | High | Low | |||||
|---|---|---|---|---|---|---|---|
| 159.25 | 160.70 | 158.40 | +2.50 | +1.59% | 144.21K | ||
| 68.56 | 68.68 | 68.24 | +0.22 | +0.32% | 898.3K | ||
| 77.94 | 78.58 | 77.18 | -0.66 | -0.84% | 185.79K | ||
| 70.42 | 70.88 | 69.88 | -0.26 | -0.37% | 232.72K | ||
| 555.60 | 565.40 | 553.60 | -14.60 | -2.56% | 114.09K | ||
| 868.00 | 868.80 | 860.60 | -3.60 | -0.41% | 16.98K | ||
| 120.86 | 120.98 | 119.80 | +0.66 | +0.55% | 484.86K | ||
| 78.54 | 79.00 | 78.30 | +0.15 | +0.19% | 394.56K | ||
| 125.80 | 126.25 | 125.25 | -0.95 | -0.75% | 148.8K | ||
| 354.20 | 356.00 | 353.40 | +0.40 | +0.11% | 129.49K | ||
| 523.60 | 526.40 | 518.20 | +7.80 | +1.51% | 28.54K | ||
| 654.50 | 660.00 | 653.50 | -2.50 | -0.38% | 12.49K | ||
| 627.20 | 631.60 | 625.20 | +3.00 | +0.48% | 8.73K | ||
| 157.85 | 158.40 | 155.30 | +2.55 | +1.64% | 112.32K | ||
| 985.80 | 987.80 | 978.00 | +7.20 | +0.74% | 13.18K | ||
| 188.65 | 190.25 | 187.85 | -1.60 | -0.84% | 30.05K | ||
| 33.88 | 34.09 | 33.78 | -0.12 | -0.35% | 603.95K | ||
| 3,092.00 | 3,105.00 | 3,017.00 | +33.00 | +1.08% | 5.24K | ||
| 60.14 | 60.78 | 60.08 | +0.06 | +0.10% | 358.7K | ||
| 45.63 | 45.64 | 45.33 | -0.13 | -0.28% | 81.33K |
Investing.com -- Goldman Sachs has shifted its ratings stance on European chemicals, moving to a more pro-cyclical view and...
Investing.com -- As the European capital goods sector heads into 2026, analysts are identifying companies well-positioned to...
Investing.com -- UBS Global Research upgraded Orior AG (SIX:ORON) to “neutral” from “sell” on Friday,...
Equity futures point higher, but bond market stress and gold strength keep risk appetite cautious. Policy relief sparks a sharp...
Amphastar Pharmaceuticals, Inc. is a U.S.-based specialty pharmaceutical company known for developing, manufacturing, and...
Want to hear something really scary? The ongoing government shutdown, now in its second month, is projected to cost the U.S....
No Earning Reports have been scheduled